99 related articles for article (PubMed ID: 29774030)
1. Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.
Aris M; Bravo AI; Pampena MB; Blanco PA; Carri I; Koile D; Yankilevich P; Levy EM; Barrio MM; Mordoh J
Front Immunol; 2018; 9():955. PubMed ID: 29774030
[TBL] [Abstract][Full Text] [Related]
2. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.
Haanen JB; Baars A; Gomez R; Weder P; Smits M; de Gruijl TD; von Blomberg BM; Bloemena E; Scheper RJ; van Ham SM; Pinedo HM; van den Eertwegh AJ
Cancer Immunol Immunother; 2006 Apr; 55(4):451-8. PubMed ID: 16034562
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.
Kidman J; Zemek RM; Sidhom JW; Correa D; Principe N; Sheikh F; Fear VS; Forbes CA; Chopra A; Boon L; Zaitouny A; de Jong E; Holt RA; Jones M; Millward MJ; Lassmann T; Forrest ARR; Nowak AK; Watson M; Lake RA; Lesterhuis WJ; Chee J
Oncoimmunology; 2024; 13(1):2345859. PubMed ID: 38686178
[TBL] [Abstract][Full Text] [Related]
5. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
Schmollinger JC; Vonderheide RH; Hoar KM; Maecker B; Schultze JL; Hodi FS; Soiffer RJ; Jung K; Kuroda MJ; Letvin NL; Greenfield EA; Mihm M; Kutok JL; Dranoff G
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3398-403. PubMed ID: 12626761
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma.
Chakraborty NG; Sporn JR; Tortora AF; Kurtzman SH; Yamase H; Ergin MT; Mukherji B
Cancer Immunol Immunother; 1998 Sep; 47(1):58-64. PubMed ID: 9755879
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
D'Alise AM; Leoni G; Cotugno G; Siani L; Vitale R; Ruzza V; Garzia I; Antonucci L; Micarelli E; Venafra V; Gogov S; Capone A; Runswick S; Martin-Liberal J; Calvo E; Moreno V; Symeonides SN; Scarselli E; Bechter O
Clin Cancer Res; 2024 Jun; 30(11):2412-2423. PubMed ID: 38506710
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.
Hunger RE; Kernland Lang K; Markowski CJ; Trachsel S; Møller M; Eriksen JA; Rasmussen AM; Braathen LR; Gaudernack G
Cancer Immunol Immunother; 2011 Nov; 60(11):1553-64. PubMed ID: 21681371
[TBL] [Abstract][Full Text] [Related]
9. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.
Anichini A; Vegetti C; Mortarini R
Cancer Immunol Immunother; 2004 Oct; 53(10):855-64. PubMed ID: 15175905
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory.
Schirrmacher V
Cancer Immunol Immunother; 2005 Jun; 54(6):587-98. PubMed ID: 15838708
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.
Gargett T; Abbas MN; Rolan P; Price JD; Gosling KM; Ferrante A; Ruszkiewicz A; Atmosukarto IIC; Altin J; Parish CR; Brown MP
Cancer Immunol Immunother; 2018 Sep; 67(9):1461-1472. PubMed ID: 30014244
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
Cipponi A; Wieers G; van Baren N; Coulie PG
Cancer Immunol Immunother; 2011 Aug; 60(8):1153-60. PubMed ID: 21553145
[TBL] [Abstract][Full Text] [Related]
13. Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
[TBL] [Abstract][Full Text] [Related]
14. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.
Cabrera T; Lara E; Romero JM; Maleno I; Real LM; Ruiz-Cabello F; Valero P; Camacho FM; Garrido F
Cancer Immunol Immunother; 2007 May; 56(5):709-17. PubMed ID: 16960691
[TBL] [Abstract][Full Text] [Related]
15. Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study.
Vissing M; Sinius Pouplier S; Munch Larsen L; Krog Frandsen S; Lodin A; Lænkholm AV; Gehl J
Acta Oncol; 2024 May; 63():398-410. PubMed ID: 38804839
[TBL] [Abstract][Full Text] [Related]
16. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
Lauss M; Donia M; Harbst K; Andersen R; Mitra S; Rosengren F; Salim M; Vallon-Christersson J; Törngren T; Kvist A; Ringnér M; Svane IM; Jönsson G
Nat Commun; 2017 Nov; 8(1):1738. PubMed ID: 29170503
[TBL] [Abstract][Full Text] [Related]
17. Distinct genomic features across cytolytic subgroups in skin melanoma.
Roufas C; Georgakopoulos-Soares I; Zaravinos A
Cancer Immunol Immunother; 2021 Nov; 70(11):3137-3154. PubMed ID: 33779796
[TBL] [Abstract][Full Text] [Related]
18. TCRβ clones in muscle tissue share structural features in patients with idiopathic inflammatory myopathy and are associated with disease activity.
Anang DC; Walter HAW; Lim J; Niewold ITG; van der Weele L; Aronica E; Eftimov F; Raaphorst J; van Schaik BDC; van Kampen AHC; van der Kooi AJ; de Vries N
Front Immunol; 2023; 14():1279055. PubMed ID: 38268914
[TBL] [Abstract][Full Text] [Related]
19. Deep sequencing of the T cell receptor β repertoire reveals signature patterns and clonal drift in atherosclerotic plaques and patients.
Lin Z; Qian S; Gong Y; Ren J; Zhao L; Wang D; Wang X; Zhang Y; Wang Z; Zhang Q
Oncotarget; 2017 Nov; 8(59):99312-99322. PubMed ID: 29245903
[TBL] [Abstract][Full Text] [Related]
20. Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.
Diaz MJ; Quach J; Song J; Milanovic S; Tran JT; Ladehoff LC; Batchu S; Whitman P; Kaffenberger BH; Montanez-Wiscovich ME
Melanoma Res; 2024 Apr; 34(2):118-124. PubMed ID: 38329217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
